"We are pleased with our third consecutive quarter of double digit revenue growth, compared to the respective periods in 2010. The planned acquisition of IRIDEX' global aesthetic business announced today, further broadens our vascular product offering, strengthens our strategy of expanding into the core-markets and provides us with cross selling opportunities to an expanded installed base of customers."






